Abstract
Human cytochrome P450 (CYP) is a superfamily of hemoproteins which oxidize a number of endogenous compounds and xenobiotics. The human CYP2C subfamily consists of four members: CYP2C8, CYP2C9, CYP2C18 and CYP2C19. CYP2C9 and CYP2C19 are important drug-metabolizing enzymes and together metabolize approximately 20% of therapeutically used drugs. Forty-two allelic variants for CYP2C9 and 34 for CYP2C19 have been reported. The frequencies of these variants show marked inter-ethnic variation. The functional consequences of genetic polymorphisms have been examined, and many studies have shown the clinical importance of these polymorphisms. Current evidence suggests that taking the genetically determined metabolic capacity of CYP2C9 and CYP2C19 into account has the potential to improve individual risk/benefit relationships. However, more prospective studies with clinical endpoints are needed before the paradigm of "personalized medicine" based on the variants can be established. This review summarizes the currently available important information on this topic.
| Original language | English |
|---|---|
| Pages (from-to) | 28-37 |
| Number of pages | 10 |
| Journal | Drug metabolism and pharmacokinetics |
| Volume | 28 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2013 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Pharmacology
- Pharmaceutical Science
- Pharmacology (medical)
Cite this
Impact of genetic polymorphisms in CYP2C9 and CYP2C19 on the pharmacokinetics of clinically used drugs. / Hirota, Takeshi; Eguchi, Shunsuke; Ieiri, Ichiro.
In: Drug metabolism and pharmacokinetics, Vol. 28, No. 1, 2013, p. 28-37.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Impact of genetic polymorphisms in CYP2C9 and CYP2C19 on the pharmacokinetics of clinically used drugs
AU - Hirota, Takeshi
AU - Eguchi, Shunsuke
AU - Ieiri, Ichiro
PY - 2013
Y1 - 2013
N2 - Human cytochrome P450 (CYP) is a superfamily of hemoproteins which oxidize a number of endogenous compounds and xenobiotics. The human CYP2C subfamily consists of four members: CYP2C8, CYP2C9, CYP2C18 and CYP2C19. CYP2C9 and CYP2C19 are important drug-metabolizing enzymes and together metabolize approximately 20% of therapeutically used drugs. Forty-two allelic variants for CYP2C9 and 34 for CYP2C19 have been reported. The frequencies of these variants show marked inter-ethnic variation. The functional consequences of genetic polymorphisms have been examined, and many studies have shown the clinical importance of these polymorphisms. Current evidence suggests that taking the genetically determined metabolic capacity of CYP2C9 and CYP2C19 into account has the potential to improve individual risk/benefit relationships. However, more prospective studies with clinical endpoints are needed before the paradigm of "personalized medicine" based on the variants can be established. This review summarizes the currently available important information on this topic.
AB - Human cytochrome P450 (CYP) is a superfamily of hemoproteins which oxidize a number of endogenous compounds and xenobiotics. The human CYP2C subfamily consists of four members: CYP2C8, CYP2C9, CYP2C18 and CYP2C19. CYP2C9 and CYP2C19 are important drug-metabolizing enzymes and together metabolize approximately 20% of therapeutically used drugs. Forty-two allelic variants for CYP2C9 and 34 for CYP2C19 have been reported. The frequencies of these variants show marked inter-ethnic variation. The functional consequences of genetic polymorphisms have been examined, and many studies have shown the clinical importance of these polymorphisms. Current evidence suggests that taking the genetically determined metabolic capacity of CYP2C9 and CYP2C19 into account has the potential to improve individual risk/benefit relationships. However, more prospective studies with clinical endpoints are needed before the paradigm of "personalized medicine" based on the variants can be established. This review summarizes the currently available important information on this topic.
UR - http://www.scopus.com/inward/record.url?scp=84874602232&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84874602232&partnerID=8YFLogxK
U2 - 10.2133/dmpk.DMPK-12-RV-085
DO - 10.2133/dmpk.DMPK-12-RV-085
M3 - Review article
C2 - 23165865
AN - SCOPUS:84874602232
VL - 28
SP - 28
EP - 37
JO - Drug Metabolism and Pharmacokinetics
JF - Drug Metabolism and Pharmacokinetics
SN - 1347-4367
IS - 1
ER -